Spyre Therapeutics, Inc. Common Stock (SYRE) is a publicly traded Healthcare sector company. As of November 3, 2026, SYRE trades at $94.38 with a market cap of $8.93B and a P/E ratio of 0.00. SYRE moved +4.00% today. Year to date, SYRE is +224.56%; over the trailing twelve months it is +317.37%. Its 52-week range spans $10.91 to $110.18. Analyst consensus is strong buy with an average price target of $122.00. Rallies surfaces SYRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Spyre Therapeutics’ Q3 loss reaches $96.12 million; cash rises to $1.5 billion: Spyre Therapeutics reported a third-quarter 2026 net loss of $96.12 million, wider than analysts’ $78.56 million estimate, as research and clinical trial costs rose. After a $400 million public offering, it ended the quarter with $1.5 billion in cash and expects runway into the second half of 2029.
| Metric | Value |
|---|---|
| Price | $94.38 |
| Market Cap | $8.93B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $110.18 |
| 52-Week Low | $10.91 |
| Volume | 646.91K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-155.20M |
| Gross Margin | 0.00% |
14 analysts cover SYRE: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $122.00.